Form 4: GoodRx Director Ronald E Bruehlman Acquires Deferred Stock Units

Director Ronald E Bruehlman of GoodRx Holdings, Inc. acquired 10,653 deferred stock units on January 1, 2025, which will vest monthly starting January 31, 2025.

Summary

• Ronald E Bruehlman, a director at GoodRx Holdings, Inc., acquired 10,653 deferred stock units on January 1, 2025.
• These deferred stock units represent a contingent right to receive one share of Class A common stock each.
• The units will vest in substantially equal monthly installments beginning on January 31, 2025, and ending on December 31, 2025, contingent on continued service.
• The deferred stock units will settle upon the earliest of several events: December 31, 2030, separation from service, a change in control, death, or disability.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction related to director compensation, which is generally viewed positively as it aligns interests. There are no negative implications.

Positives

• The acquisition of deferred stock units aligns the director's interests with the long-term performance of the company.
• The vesting schedule encourages continued service from the director.

Risks

• The value of the deferred stock units is subject to the market price of GoodRx's Class A common stock.
• The director's continued service is required for the vesting of the units.

Future Outlook

The deferred stock units will vest over the course of 2025, subject to continued service, and will settle no later than December 31, 2030, or upon earlier triggering events.

Industry Context

This is a standard practice for aligning the interests of directors with the company's performance through equity-based compensation.

Comparison to Industry Standards

• Deferred stock units are a common form of equity compensation for directors in publicly traded companies.
• The vesting schedule and settlement terms are typical for such grants, designed to incentivize long-term commitment and performance.
• Many companies, such as those in the technology and healthcare sectors, use similar equity-based compensation plans for their directors.

Stakeholder Impact

• The acquisition of deferred stock units by a director is generally viewed positively by shareholders as it aligns interests.
• The vesting schedule encourages continued service from the director, which benefits the company.

Next Steps

• The director will continue to vest in the deferred stock units over the course of 2025.
• The deferred stock units will settle upon the earliest of the specified events.

Key Dates

Keywords

GoodRx, Deferred Stock Units, Director, GDRX, Stock Acquisition, Vesting, Class A Common Stock